In an international, multicenter collaboration, experts modified the RECIST criteria for use as objective endpoints in clinical trials of retinoblastoma therapies.
Cancer Therapy Advisor interviewed Dr Dyer about recent study results relating to the retinoblastoma epigenome and an important finding about the timing of retinoblastoma development.
Periocular basal cell carcinomas (pBCCs) have a mean growth rate of 11.2 mm² every 30 days.
In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall surviva.
Researchers have identified a therapeutic target for treating the most common form of eye cancer in adults.
Young children with retinoblastoma treated with systemic carboplatin have a higher incidence of ototoxicity than previously reported, calling for routine, thorough, long-term audiologic monitoring, a study in the Journal of Clinical Oncology published online February 27 reported.
